VALIDATE Network Manager
Sam is the VALIDATE Network Manager. VALIDATE is an international research network led by Professors Helen McShane (University of Oxford) and Samantha Sampson (Stellenbosch University) aiming to accelerate vaccine development for neglected intracellular pathogens, with an initial focus on TB, leishmaniasis, melioidosis and leprosy. The network also aims to build capacity in LMICs, connect industry and academia, and facilitate career development for Early Career Researchers. VALIDATE is OneHealth and interdisciplinary so welcomes anyone working on any research area that could inform vaccine development for our focus pathogens. We now have over 550 members in more than 70 countries worldwide forming an engaged and interactive community. Find out more about VALIDATE at www.validate-network.org.
Previously the Jenner Institute’s TB Vaccine Programme Manager, Sam has extensive experience in project management, managing clinical trials in the UK and overseas, research grant management, working with industry partners, and managing Consortiums. Do get in contact with her for any queries about VALIDATE.
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY
Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018)
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy
Fletcher HA. et al, (2018), F1000Research, 7, 485 - 485